National Consensus for Screening, Diagnosis and Management of Hepatocellular Carcinoma in Panama, 2022

Abstract

Introduction
Hepatocellular carcinoma (HCC) is considered the main primary neoplasm of the liver and its incidence is expected to increase in
the next years. HCC is frequently associated with chronic liver disease secondary to hepatitis B or C infections, as well to alcohol
abuse, fatty liver and metabolic syndrome. Multidisciplinary and individualized management has been shown to improve clinical
outcome; nevertheless, in Panama and others Latin-American countries, there is no clear consensus for the management of this
disease.
Methodology
Using Appraisal of Guidelines for REsearch and Evaluation II (AGREE II) methodology and the Institute of Medicine (IOM)
criteria, we developed a multidisciplinary consensus for the management of hepatocarcinoma patients in Panama.
Results
This document synthesizes the current evidence on risk factors in conjunction with recommendations on the management of
early, advanced and terminal disease. All healthcare personnel involved in the approach and treatment of hepatocarcinoma in
Panama can find utility and applicability in their daily practice.
Conclusion
Here, we present the first National Consensus for the Screening, Diagnosis and Treatment of Hepatocellular Carcinoma in
Panama.